AML clinical trial intelligence

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy and in Combination With Azacitidine in Subjects With Advanced Hematologic Malignancies

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy and in Combination With Azacitidine in Subjects With Advanced Hematologic Malignancies is a PHASE1 clinical asset sponsored by AbbVie (prior sponsor, Abbott) in Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, B-cell Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia. SEO and diligence focus: ABT-348, ABT-348, ABT-348 and azacitidine, ABT-348, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Acute Myelogenous Leukemia

A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia

A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia is a PHASE2 clinical asset sponsored by M.D. Anderson Cancer Center in Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, de Novo Myelodysplastic Syndrome, High Risk Myelodysplastic Syndrome, Inv(16), Myelodysplastic Syndrome With Excess Blasts, t(16;16), t(8;21), Untreated Adult Acute Myeloid Leukemia. SEO and diligence focus: Cytarabine, Decitabine, Filgrastim-sndz, Fludarabine Phosphate, Gemtuzumab Ozogamicin, Idarubicin, Laboratory Biomarker Analysis, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia

A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia is a PHASE4 clinical asset sponsored by Changhai Hospital in Acute Myeloid Leukemia, AML1-ETO Fusion Protein Expression. SEO and diligence focus: Fludarabine, Cytarabine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Acute Myeloid Leukemia

A Phase II Study of Bortezomib and Vorinostat in Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

A Phase II Study of Bortezomib and Vorinostat in Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies is a PHASE2 clinical asset sponsored by St. Jude Children's Research Hospital in Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoid Leukemia. SEO and diligence focus: Bortezomib, Vorinostat, Mitoxantrone, Cytarabine, Methotrexate, Hydrocortisone, Peg-L-Asparaginase, Erwinia L-Asparaginase, Dexamethasone, Mercaptopurine, Doxorubicin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Acute Myeloid Leukemia

Phase 1/2 Study of Decitabine Combined With Modified CAG Followed by HLA Haploidentical T Cell Infusion in Treating Elderly Patients With Intermediate-high Risk Myelodysplastic Syndrome(MDS) or Acute Myeloid Leukemia(AML）

Phase 1/2 Study of Decitabine Combined With Modified CAG Followed by HLA Haploidentical T Cell Infusion in Treating Elderly Patients With Intermediate-high Risk Myelodysplastic Syndrome(MDS) or Acute Myeloid Leukemia(AML） is a PHASE1 clinical asset sponsored by Chinese PLA General Hospital in MDS, AML. SEO and diligence focus: Decitabine, Cytarabine, aclacinomycin, Granulocyte colony-stimulating factor, HLA haploidentical mononuclear cells infusion, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: AML

A Pilot Study of Low-Dose Daunorubicin in Patients With Relapsed/Refractory Acute Leukemia

A Pilot Study of Low-Dose Daunorubicin in Patients With Relapsed/Refractory Acute Leukemia is a PHASE1 clinical asset sponsored by Tara Lin in Acute Lymphocytic Leukemia, Acute Myeloid Leukemia. SEO and diligence focus: Daunorubicin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Acute Myeloid Leukemia

Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies

Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies is a PHASE2 clinical asset sponsored by H. Lee Moffitt Cancer Center and Research Institute in Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Myeloproliferative Neoplasm, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Relapsed Marginal B-cell Lymphoma, Relapsed Follicular Lymphoma, Lymphoplasmacytic Lymphoma. SEO and diligence focus: Fludarabine, Melphalan, Total Body Irradiation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor (APTBCy)

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor (APTBCy) is a PHASE2 clinical asset sponsored by St. Petersburg State Pavlov Medical University in Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia, Myelodysplastic Syndromes (MDS), Myeloprolipherative Neoplsm, Atypical Chronic Myeloid Leukemia. SEO and diligence focus: Ruxolitinib, Abatacept (Orencia), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Acute Myeloid Leukemia (AML)

Phase I/II Study of Plerixafor and Clofarabine in Previously Untreated Older (>/=60 Years) Adult Patients With Acute Myelogenous Leukemia (AML) With Two or More Unfavorable Prognostic Factors for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit

Phase I/II Study of Plerixafor and Clofarabine in Previously Untreated Older (>/=60 Years) Adult Patients With Acute Myelogenous Leukemia (AML) With Two or More Unfavorable Prognostic Factors for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit is a PHASE1 clinical asset sponsored by M.D. Anderson Cancer Center in Acute Myelogenous Leukemia. SEO and diligence focus: Plerixafor, Clofarabine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Acute Myelogenous Leukemia

Two-Step Remission Induction With Risk-Oriented Consolidation (High-Risk: Allogeneic Stem Cell Transplant; Standard-Risk: Multicycle High-Dose Cytarabine With Autologous Blood Stem Cell Support) for Adult Acute Myelogenous Leukemia

Two-Step Remission Induction With Risk-Oriented Consolidation (High-Risk: Allogeneic Stem Cell Transplant; Standard-Risk: Multicycle High-Dose Cytarabine With Autologous Blood Stem Cell Support) for Adult Acute Myelogenous Leukemia is a PHASE2 clinical asset sponsored by Northern Italy Leukemia Group in Acute Myelogenous Leukemia. SEO and diligence focus: Two-step remission induction and risk-oriented consolidation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Acute Myelogenous Leukemia

Venetoclax, Azacitidine Combined With Homoharringtonine Versus Venetoclax and Azacitidine in Newly Diagnosed Elderly (60-75 Years) Acute Myeloid Leukemia: A Multicenter, Open-label, Randomized, Controlled Clinical Trial

Venetoclax, Azacitidine Combined With Homoharringtonine Versus Venetoclax and Azacitidine in Newly Diagnosed Elderly (60-75 Years) Acute Myeloid Leukemia: A Multicenter, Open-label, Randomized, Controlled Clinical Trial is a PHASE3 clinical asset sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine in Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years). SEO and diligence focus: Venetoclax, Azacitidine, Homoharringtonine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Acute Myeloid Leukemia (AML)

A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies

A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies is a PHASE1 clinical asset sponsored by Shenzhen Geno-Immune Medical Institute in T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma. SEO and diligence focus: CD7-specific CAR gene-engineered T cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Acute Myeloid Leukemia

The Safety and Efficacy for Anti-human CLL-1 CAR-NK Cells in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

The Safety and Efficacy for Anti-human CLL-1 CAR-NK Cells in Subjects With Relapsed/Refractory Acute Myeloid Leukemia is a PHASE1 clinical asset sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine in Relapsed Adult AML, Refractory AML. SEO and diligence focus: anti-CLL-1 CAR NK cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Relapsed Adult AML

Phase I Study of Escalating Doses of 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Phase I Study of Escalating Doses of 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome is a PHASE1 clinical asset sponsored by City of Hope Medical Center in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome. SEO and diligence focus: Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Daratumumab, Echocardiography, Fludarabine, Hematopoietic Cell Transplantation, Indium In 111-DOTA-Daratumumab, Melphalan, Multigated Acquisition Scan, Radionuclide Imaging, Single Photon Emission Computed Tomography, Sirolimus, Tacrolimus, Total Marrow and Lymphoid Irradiation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Dendritic Cell-based Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Cells Transfected With RNA Encoding Two Different Leukemia-associated Antigens

Dendritic Cell-based Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Cells Transfected With RNA Encoding Two Different Leukemia-associated Antigens is a PHASE1 clinical asset sponsored by Medigene AG in Acute Myeloid Leukemia. SEO and diligence focus: WT1/PRAME vaccination, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Acute Myeloid Leukemia

MRD-guided Treatment With Pembrolizumab and Azacitidine in NPM1mut AML Patients With an Imminent Hematological Relapse

MRD-guided Treatment With Pembrolizumab and Azacitidine in NPM1mut AML Patients With an Imminent Hematological Relapse is a PHASE2 clinical asset sponsored by Technische Universität Dresden in Acute Myeloid Leukemia. SEO and diligence focus: Pembrolizumab, Azacitidine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Acute Myeloid Leukemia

A Multi-Center, Prospective, Single-Arm, Phase 2 Clinical Study on the Efficacy and Safety of Lisafotoclax Combined With Decitabine and Homoharringtonine in Patients With Acute Myeloid Leukemia Previously Treated With Venetoclax Combined With Azacitidine Regimen

This Phase 2 clinical trial is positioned to evaluate a novel combination therapy for AML patients who have previously failed or are intolerant to the Venetoclax plus Azacitidine regimen. The target patient population is significant, given the high unmet medical need in relapsed/refractory AML. If successful, this combination could provide a competitive edge in a market dominated by limited treatment options for this patient demographic. The trial's location in China may also offer strategic advantages in terms of regulatory pathways and market entry, particularly in the Asia-Pacific region, which is experiencing rapid growth in oncology therapeutics. Companies should monitor the trial's progress closely for potential partnership or acquisition opportunities, especially if the results demonstrate a favorable safety and efficacy profile.

Phase 2 Study of 5 Days Azacytidine Priming Prior to Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor (G-CSF) Combination for Patients With Relapsed or Refractory AML

The Phase 2 study sponsored by King Fahad Medical City aims to evaluate the efficacy of azacytidine in combination with fludarabine, cytarabine, and G-CSF for patients with relapsed or refractory AML. Given the high unmet medical need in this patient population, successful outcomes could position this combination therapy favorably in the competitive landscape of AML treatments. The market for AML therapies is growing, driven by advancements in targeted therapies and immunotherapies. Companies developing treatments for AML should closely monitor this trial's results as they may influence treatment paradigms and competitive positioning. Additionally, the trial's location in Saudi Arabia may provide insights into regional market dynamics and patient access considerations.

Matched by conditions: Acute Myeloid Leukemia

Fludarabine and Cytarabine as Continuous Infusion Plus Idarubicin With Granulocyte-Colony Stimulating Factor (G-CSF) Priming for Patients Younger Than 60 Years With Resistant Acute Myeloid Leukemia

This clinical trial, sponsored by the Cooperative Study Group A for Hematology, aims to evaluate the feasibility and efficacy of a combination therapy (FLAG+Ida) in patients younger than 60 years with resistant AML. Given the high unmet medical need in this patient population, successful outcomes could position this treatment as a competitive option in the AML market, which is characterized by a growing demand for effective therapies. The trial's focus on younger patients with resistant disease may also attract interest from pharmaceutical companies looking to expand their oncology portfolios. However, the overall status of the trial remains 'unknown,' which may raise concerns regarding recruitment and potential delays in data availability.

Matched by conditions: Acute Myeloid Leukemia

A Phase II Open-Label, Single Center Trial of Oral Decitabine-Cedazuridine (DEC-C) (Inqovi®) in Combination With Thioguanine (Tabloid®) in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

The trial, sponsored by Columbia University, aims to evaluate the safety and efficacy of a combination therapy involving oral decitabine-cedazuridine and thioguanine in patients with relapsed or refractory AML. The market for AML therapies is significant, with a high unmet need for effective treatments, particularly in relapsed cases where current options yield low response rates. The withdrawal of the trial due to difficulties in enrollment may indicate challenges in patient recruitment, potentially impacting the commercial viability of this combination therapy. Competitively, the landscape includes established therapies and emerging agents, necessitating a robust differentiation strategy for any successful outcomes from this trial.

Matched by conditions: Acute Myeloid Leukemia

Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

The trial investigates the efficacy of combining venetoclax with the standard treatment of ivosidenib and azacitidine in patients with newly diagnosed IDH1-mutated AML or MDS/AML who are ineligible for intensive chemotherapy. The market for AML treatments is competitive, with several existing therapies, including targeted agents and hypomethylating agents. Should the combination therapy demonstrate improved outcomes, it could capture significant market share, particularly among older patients and those with comorbidities who are unable to tolerate intensive chemotherapy. The collaboration with multiple European study groups enhances the trial's credibility and recruitment potential, positioning it favorably in the competitive landscape.

Matched by conditions: Acute Myeloid Leukemia

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients: A Single Arm, Multi Center Clinical Trial

The clinical trial, sponsored by The First Affiliated Hospital of Soochow University, is investigating the efficacy of HMA maintenance therapy in patients with favorable-risk Acute Myeloid Leukemia (AML). Given the increasing incidence of AML and the limited treatment options for this patient population, successful outcomes could position the sponsor as a leader in the HMA market. The trial's focus on overall survival (OS) and relapse-free survival (RFS) could enhance the commercial viability of Azacitidine and Decitabine, particularly in the context of personalized medicine. The competitive landscape includes other emerging therapies targeting AML, necessitating robust data to demonstrate superiority or added benefit. Diligence should focus on regulatory pathways and potential market access challenges in various jurisdictions.

A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination With ASTX727 in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

The ongoing Phase I trial sponsored by the National Cancer Institute (NCI) evaluates the safety and efficacy of cirtuvivint as a monotherapy and in combination with ASTX727 for treating relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Given the high unmet medical need in these indications, successful outcomes could position cirtuvivint as a competitive option in a market with limited effective therapies. The trial's focus on both monotherapy and combination therapy may enhance its commercial viability, particularly if it demonstrates improved safety and efficacy profiles compared to existing treatments. Stakeholders should monitor enrollment and preliminary efficacy data closely, as these will inform future development strategies and potential partnerships.

Phase II Study of 852A Administered Subcutaneously in Patients With Hematologic Malignancies Not Responding to Standard Treatment

The Phase II study of 852A, sponsored by the Masonic Cancer Center at the University of Minnesota, aimed to evaluate the anti-tumor activity in patients with hematologic malignancies unresponsive to standard treatments. The study was terminated due to the unavailability of the drug, which raises concerns about the asset's viability and future development potential. Given the competitive landscape of hematologic malignancies, where numerous therapies are in development, the lack of progress may hinder the asset's market entry. Companies focusing on similar indications may pose competitive threats, necessitating diligence in assessing the potential for re-engagement or acquisition of this asset.

Matched by conditions: Acute Myeloid Leukemia

An Open-label, Multi-Center, Phase IIIb Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia Who Are Eligible for "7+3" or "5+2" Chemotherapy

Midostaurin (PKC412), developed by Novartis Pharmaceuticals, targets FLT3 mutations in AML, a significant market segment with unmet needs. The combination of midostaurin with standard chemotherapy regimens (7+3 or 5+2) aims to improve patient outcomes in newly diagnosed FLT3-mutated AML. The study's completion and the anticipated results could strengthen Novartis's position in the oncology market, particularly against competitors like Astellas and Daiichi Sankyo, which also target FLT3 mutations. Successful outcomes may enhance market access and reimbursement opportunities, while potential adverse events could impact market perception and adoption.

Matched by conditions: Acute Myeloid Leukemia

2157GCCC: a Phase I Trial of Calaspargase Pegol-mknl in Combination with High Dose Cytarabine and Idarubicin in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia

The Phase 1 trial of Calaspargase Pegol-mknl in combination with high-dose Cytarabine and Idarubicin is aimed at establishing the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) for adult patients with newly diagnosed AML. Given the high unmet need in AML treatment, particularly for patients who are refractory to standard therapies, successful outcomes could position Calaspargase Pegol-mknl as a novel therapeutic option in a competitive market. The trial is sponsored by West Virginia University, and the results could have significant implications for further development and potential commercialization, especially if the drug demonstrates a favorable safety and efficacy profile compared to existing therapies.

Matched by conditions: Acute Myeloid Leukemia

Phase I Study of Escalating Doses of 90Y-DOTA-Anti-CD25 Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan, and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Leukemia or Myelodysplastic Syndrome

The Phase I trial of 90Y-DOTA-anti-CD25 basiliximab, in combination with fludarabine, melphalan, and total marrow and lymphoid irradiation (TMLI), aims to enhance outcomes for patients with high-risk acute leukemia or myelodysplastic syndrome. Given the high unmet need in this patient population, successful results could position the asset favorably in the hematologic malignancy treatment landscape. The collaboration with the National Cancer Institute (NCI) may enhance credibility and facilitate future funding opportunities. However, the competitive landscape includes established therapies and emerging agents targeting similar pathways, necessitating a robust differentiation strategy. The trial's focus on a specific patient demographic (age ≥ 60 years or younger with comorbidities) may limit market size but could also streamline regulatory pathways if successful.

Phase 1 Study of IACS-010759 in Subjects With Relapsed or Refractory AML

IACS-010759, an oxidative phosphorylation inhibitor, was evaluated in a Phase 1 trial for relapsed or refractory acute myeloid leukemia (AML). The trial was sponsored by M.D. Anderson Cancer Center and aimed to establish the maximum tolerated dose and assess safety and efficacy. However, the study was terminated due to a lack of effectiveness, indicating potential challenges in market viability. The competitive landscape for AML treatments remains robust, with multiple therapies available, necessitating a thorough diligence review for any future development or licensing opportunities.

Matched by conditions: Recurrent Acute Myeloid Leukemia

Clinical Phase II Trial to Describe the Safety and Efficacy of Treosulfan-based Conditioning Therapy Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Paediatric Patients With Haematological Malignancies

The Phase II trial conducted by medac GmbH evaluates the safety and efficacy of Treosulfan-based conditioning therapy prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) in pediatric patients with hematological malignancies. Given the high unmet medical need in this patient population, successful outcomes could position Treosulfan as a preferred conditioning agent, potentially increasing market share in the pediatric oncology segment. The competitive landscape includes other conditioning regimens, but Treosulfan's reduced toxicity profile may offer a significant advantage. Diligence considerations should focus on the trial's safety data, long-term outcomes, and potential regulatory pathways for pediatric indications.

Matched by conditions: Acute Myeloid Leukaemias (AML)

A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

SNDX-5613, a menin inhibitor, is being evaluated in combination with standard chemotherapy (daunorubicin and cytarabine) for newly diagnosed acute myeloid leukemia (AML) patients with specific genetic alterations (NPM1 mutations, MLL/KMT2A rearrangements, or NUP98 alterations). The trial's focus on high-risk AML patients positions it strategically within a niche market, potentially addressing unmet needs in a competitive landscape dominated by existing therapies. The combination approach may enhance efficacy and improve patient outcomes, which could lead to a favorable market entry if successful. The trial is sponsored by the National Cancer Institute, indicating a robust backing that may enhance credibility and attract further investment or partnerships.

Matched by conditions: Acute Myeloid Leukemia

Pilot Study of the Efficacy and Safety of CD38 Targeted Chimeric Antigen Receptor Engineered T-Cells in the Treatment of CD38 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

The pilot study evaluates CD38-targeted CAR T-cell therapy for relapsed or refractory acute myeloid leukemia (AML), a significant unmet medical need in hematological malignancies. The study's single-center design and open-label nature may limit generalizability but allows for focused data collection. The target population of CD38 positive AML patients presents a niche market opportunity, particularly as existing therapies may not effectively address relapsed cases. Competitive landscape analysis indicates a growing interest in CAR T-cell therapies, with several companies pursuing similar targets. Successful outcomes could position the sponsor favorably for partnerships or licensing agreements, enhancing their portfolio in immuno-oncology.

Matched by conditions: Acute Myeloid Leukemia

A Phase I/II Study to Evaluate the Safety and Efficacy of Anti-CLL1-CD33-NKG2D Bicephali CAR-T Cells in Patients With Relapsed/Refractory Acute Myeloid Leukemia

The clinical trial sponsored by Xuzhou Medical University aims to evaluate a novel CAR-T cell therapy targeting relapsed/refractory acute myeloid leukemia (AML). Given the high unmet medical need in this patient population, successful outcomes could position this therapy as a competitive alternative to existing treatments, potentially capturing significant market share in the CAR-T space. The collaboration with Yake Biotechnology Ltd. may enhance development capabilities and commercialization prospects. However, the trial's not-yet-recruiting status indicates that market entry is still several years away, with estimated completion in 2029. Stakeholders should monitor the evolving landscape of AML therapies and the competitive positioning of this asset as it progresses through clinical development.

Matched by conditions: AML (Acute Myeloid Leukemia)

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

This clinical trial, sponsored by M.D. Anderson Cancer Center, aims to evaluate the safety and efficacy of CAR.70-engineered IL15-transduced cord blood-derived NK cells in combination with lymphodepleting chemotherapy for patients with relapse/refractory hematological malignancies. The targeted patient population includes those with specific CD70 expression, which may represent a significant market opportunity given the high unmet need in hematological cancers such as leukemia, lymphoma, and multiple myeloma. The trial's focus on a novel CAR NK cell therapy positions it competitively within the expanding field of cell therapies, particularly against existing therapies that may not effectively target CD70-expressing tumors. Successful outcomes could lead to further development and commercialization, potentially enhancing M.D. Anderson's reputation as a leader in innovative cancer treatments.

A Phase 1 Study of Milademetan in Combination With Quizartinib in Subjects With FLT3-ITD Mutant Acute Myeloid Leukemia That Are Relapsed/Refractory, or Newly Diagnosed and Unfit for Intensive Chemotherapy

Daiichi Sankyo's Phase 1 study of milademetan in combination with quizartinib targets FLT3-ITD mutant AML, a significant segment of the leukemia market. The combination therapy aims to enhance efficacy over monotherapy, potentially positioning Daiichi Sankyo favorably against competitors in the AML treatment landscape. However, the study was terminated based on a business decision, which raises concerns regarding the commercial viability and future investment in this asset. The termination may reflect strategic realignment or challenges in achieving desired clinical outcomes, necessitating careful diligence for stakeholders considering involvement in this therapeutic area.

Matched by conditions: Acute Myeloid Leukemia

Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil

The clinical trial, sponsored by Fred Hutchinson Cancer Center, targets patients with hematopoietic cancers who are not eligible for autologous transplantation or have failed prior treatments. The approach combines fludarabine phosphate with low-dose total-body irradiation and donor stem cell infusion, potentially positioning it as a novel treatment option in the hematologic oncology market. Given the increasing prevalence of hematologic malignancies and the limitations of current therapies, successful outcomes could lead to significant market opportunities. However, the competitive landscape includes established therapies and emerging treatments, necessitating thorough diligence on efficacy, safety, and reimbursement pathways.

Matched by conditions: Recurrent Adult Acute Myeloid Leukemia

A Prospective, Multicenter Umbrella Study Based on Molecular Genetics to Guide the Efficacy and Safety of Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia/Myelodysplastic Syndrome

This multicenter umbrella study sponsored by Ruijin Hospital aims to evaluate the efficacy and safety of tailored maintenance therapies for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) post-allogeneic hematopoietic stem cell transplantation. The study is designed to enroll 126 subjects, leveraging genomic sequencing to stratify patients into distinct treatment arms based on their molecular profiles. Given the increasing focus on personalized medicine in oncology, this trial positions Ruijin Hospital at the forefront of AML/MDS treatment innovation. The potential for successful outcomes could enhance market positioning and attract partnerships or investments, particularly in the context of precision oncology. The competitive landscape includes existing therapies targeting similar mutations, necessitating a thorough analysis of differentiation and clinical efficacy to secure a favorable market entry.

Clinical Study of Targeting CD123 Chimeric Antigen Receptor Natural Killer Cells (CAR-NK) in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Chongqing Precision Biotech Co., Ltd is advancing a promising CAR-NK cell therapy targeting CD123 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). The market for AML therapies is significant, with a growing demand for innovative treatments due to high relapse rates and limited options for refractory cases. The competitive landscape includes established therapies such as chemotherapy and emerging CAR-T cell therapies. Successful outcomes in this trial could position Chongqing Precision Biotech favorably against competitors, potentially leading to strategic partnerships or acquisition interest. Diligence considerations should focus on regulatory pathways, manufacturing capabilities, and the scalability of CAR-NK cell production.

Matched by conditions: Acute Myeloid Leukemia

A Phase I Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)

DT388GMCSF represents a novel therapeutic approach targeting refractory Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) through a fusion protein mechanism. The market for AML therapies is significant, with ongoing demand for innovative treatments due to high unmet needs in relapsed and refractory cases. The competitive landscape includes established therapies and emerging agents, necessitating a thorough diligence process to assess DT388GMCSF's potential positioning and differentiation. The trial's termination due to slow accrual raises concerns regarding market viability and investor interest, suggesting a need for strategic reevaluation or potential partnership opportunities to enhance recruitment and development pathways.

Matched by conditions: Acute Myelogenous Leukemia

Phase 1/2a, Single Dose Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia

Intellia Therapeutics' NTLA-5001 is positioned within the competitive landscape of CAR-T and TCR therapies for Acute Myeloid Leukemia (AML). The termination of this trial indicates a strategic pivot towards an allogeneic version of the therapy, which may enhance scalability and address manufacturing challenges associated with autologous therapies. The AML market is characterized by a growing demand for innovative treatments, particularly in relapsed/refractory cases, suggesting potential for significant market capture if the allogeneic version demonstrates safety and efficacy. Stakeholders should monitor developments closely as the allogeneic approach may offer a competitive edge over existing therapies.

Matched by conditions: Acute Myeloid Leukemia

Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of Secondary Acute Myeloid Leukemia

The clinical trial evaluates a novel combination therapy of Venetoclax, Azacitidine, and Harringtonine for secondary acute myeloid leukemia (sAML), a patient population with limited treatment options. Given the FDA's prior approval of Venetoclax in combination with Azacitidine for elderly patients with newly diagnosed AML, this trial could position the combination as a competitive treatment option for younger patients with sAML. The anticipated enrollment of 30 patients and the focus on efficacy and safety could provide valuable data to support potential market entry. The trial's outcomes may influence treatment guidelines and establish a new standard of care, thereby impacting market dynamics and competitive positioning in the hematologic oncology space.

Matched by conditions: Secondary Acute Myeloid Leukemia

Sequential Gilteritinib in Combination With Venetoclax and Azacitidine for Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and FLT3 Mutations Ineligible for Intensive Treatment

The clinical trial, sponsored by Technische Universität Dresden, investigates the combination of Gilteritinib, Venetoclax, and Azacitidine in patients with newly diagnosed AML harboring FLT3 mutations who are ineligible for intensive chemotherapy. This patient population represents a significant unmet medical need, as current treatment options are limited for those unable to tolerate standard induction chemotherapy. The trial's focus on optimizing dosing regimens may enhance therapeutic outcomes and improve market positioning for Gilteritinib in the competitive landscape of AML therapies. Given the increasing prevalence of AML and the growing market for targeted therapies, successful trial outcomes could lead to expanded indications and increased market share for the involved compounds.

Matched by conditions: AML - Acute Myeloid Leukemia

A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy

The clinical trial for alvocidib, sponsored by Sumitomo Pharma America, Inc., was aimed at evaluating its efficacy in patients with relapsed or refractory acute myeloid leukemia (AML) following treatment with venetoclax combination therapy. However, the study was terminated due to a business decision on November 17, 2020, with the last patient follow-up completed by May 14, 2021. This termination indicates potential challenges in the commercial viability of alvocidib, particularly in a competitive landscape where other therapies for AML, including venetoclax, are gaining traction. The decision to halt development may reflect insufficient efficacy or safety data to support further investment, necessitating a thorough review of the competitive landscape and market positioning for alternative therapies targeting AML.

Matched by conditions: Acute Myeloid Leukemia (AML)

Multi-center, Open Label, Randomized Trial Comparing Single Versus Double Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia (BMT CTN #0501)

The trial, sponsored by the Medical College of Wisconsin, investigates the efficacy of single versus double umbilical cord blood transplantation in pediatric patients with high-risk leukemia and myelodysplasia. Given the increasing prevalence of hematologic malignancies in children and the potential for improved outcomes with double UCB transplants, this study could significantly impact treatment protocols and market dynamics in pediatric oncology. Successful results may enhance the competitive positioning of UCB transplantation as a standard of care, potentially influencing reimbursement policies and attracting interest from biopharma companies focused on hematological therapies.

Matched by conditions: Acute Myelogenous Leukemia

A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

AG-120, an oral agent targeting IDH1 mutations, is currently in a Phase I clinical trial sponsored by Servier, focusing on advanced hematologic malignancies. The trial's dual-phase design allows for both dose escalation and expansion, which could provide critical data on safety and efficacy. Given the increasing prevalence of IDH1 mutations in hematologic cancers, AG-120 has the potential to capture a significant share of the market for targeted therapies in this space. The competitive landscape includes other IDH inhibitors such as ivosidenib, necessitating a robust differentiation strategy based on clinical outcomes and safety profiles. Diligence should focus on the trial's progress, patient recruitment rates, and any emerging data that could influence market positioning.

Matched by conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Phase 1, Open-Label, Multicentre, Non-Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD4573, a Potent and Selective CDK9 Inhibitor, in Subjects With Relapsed or Refractory Haematological Malignancies

AZD4573, a selective CDK9 inhibitor developed by AstraZeneca, targets relapsed or refractory hematological malignancies, including various forms of leukemia and lymphoma. The asset is positioned in a competitive landscape where CDK inhibitors are gaining traction due to their potential to modulate transcriptional regulation in cancer cells. The market for hematological malignancies is significant, with increasing incidence rates and a growing demand for novel therapies. AstraZeneca's investment in this asset reflects a strategic focus on expanding its oncology portfolio, particularly in areas with high unmet medical needs. The successful outcomes from this trial could enhance AstraZeneca's market position and provide leverage in negotiations with potential partners or acquirers.

Matched by conditions: Acute Myeloid Leukemia

A Phase 2, Prospective, Multi-center Intervention Trial in Patients With Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasms Unfit for Intensive Chemotherapy Investigating a Treatment Combination Including Decitabine and Venetoclax

The trial investigates a combination therapy of Venetoclax (VEN) and Decitabine (DEC) for patients with acute myeloid leukemia (AML) secondary to myeloproliferative neoplasms (MPNs) who are unfit for intensive chemotherapy. Given the high unmet need in this patient population, successful outcomes could position this combination regimen as a significant treatment option in a niche market. The competitive landscape includes existing therapies for AML, but the specific targeting of sAML with this combination may provide a unique selling proposition. Diligence should focus on the trial's efficacy and safety data, as well as potential regulatory pathways for accelerated approval based on the high unmet need.

Matched by conditions: Acute Myeloid Leukemia

Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies

This clinical trial, sponsored by Memorial Sloan Kettering Cancer Center, aims to evaluate the efficacy of Cord Blood Transplantation (CBT) in children and young adults with high-risk hematologic malignancies. The study is currently recruiting participants, indicating a proactive approach to addressing a significant unmet medical need in this demographic. The potential success of CBT could position Memorial Sloan Kettering as a leader in pediatric hematologic oncology, enhancing its reputation and attracting further funding and partnerships. The market for hematologic malignancies is substantial, with increasing demand for innovative therapies, particularly in the pediatric segment. Competitive implications include the need to monitor other emerging therapies in the space, such as CAR-T cell therapies and other transplant modalities, which may pose challenges or opportunities for collaboration.

Matched by conditions: Acute Myelogenous Leukemia

An Open-label Phase 1b Study of PF-04449913 (Glasdegib) in Combination With Azacitidine in Patients With Previously Untreated Higher-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

The combination of PF-04449913 (Glasdegib) with azacitidine is being explored for its potential to enhance treatment outcomes in higher-risk MDS, AML, and CMML patients. Given the high unmet medical need in these populations, successful results could position Pfizer favorably in the hematological malignancies market, which is characterized by significant competition from existing therapies such as hypomethylating agents and novel agents like venetoclax. The completion of this trial may provide critical data to support regulatory submissions and market access strategies, enhancing Pfizer's portfolio in oncology.

Matched by conditions: Acute Myeloid Leukemia

A Phase 1 Dose-Escalation Study of LAM-003 in Patients With Acute Myeloid Leukemia

LAM-003 is currently in Phase 1 clinical trials for the treatment of Acute Myeloid Leukemia (AML). The market for AML therapies is competitive, with several established treatments and emerging therapies. The successful completion of this trial could position OrphAI Therapeutics favorably in a market that is increasingly focused on novel agents for relapsed or refractory AML. Given the limited treatment options for patients with relapsed AML, LAM-003 may address a significant unmet need, potentially enhancing its commercial viability. Diligence should focus on the safety profile, efficacy outcomes, and the competitive landscape, particularly regarding other investigational agents in similar stages of development.

Matched by conditions: Acute Myeloid Leukemia

A Single-Arm, Multicenter, Open-Label, Dose- Escalating and Expanding,Phase I/II Study of SKLB1028 Combined With "7+3" Standard Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

SKLB1028, developed by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., is currently undergoing a Phase I/II clinical trial to evaluate its safety, tolerability, and pharmacokinetics when combined with the standard '7+3' chemotherapy regimen in patients with newly diagnosed AML. The trial is particularly focused on patients with FLT3 mutations, a significant subset of AML that represents a substantial market opportunity due to the high unmet need for effective therapies. The competitive landscape includes other FLT3 inhibitors such as midostaurin and gilteritinib, which have established their efficacy in this patient population. Successful outcomes from this trial could position SKLB1028 as a viable treatment option, potentially enhancing CSPC's portfolio in the oncology space and providing a strategic advantage in the growing AML market.

Matched by conditions: Newly Diagnosed Acute Myeloid Leukemia (AML)

A Phase I/II Study of Midostaurin (PKC412) and 5-Azacitidine for Elderly Patients With Acute Myelogenous Leukemia.

The combination of midostaurin (PKC412) and azacitidine presents a promising therapeutic strategy for elderly patients with acute myelogenous leukemia (AML), particularly those who are unfit for standard induction chemotherapy. Given the increasing incidence of AML in the aging population, this combination therapy could capture a significant share of the market for AML treatments. The trial's completion and subsequent results may enhance the competitive positioning of midostaurin, especially against existing therapies like decitabine and other hypomethylating agents. Diligence should focus on the safety profile, efficacy outcomes, and potential market entry strategies, particularly in light of the evolving landscape of AML treatments and the need for novel therapeutic options for elderly patients.

Matched by conditions: Untreated Adult Acute Myeloid Leukemia

A Phase 3, Randomized, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 60 Years

This Phase 3 clinical trial is sponsored by The First Affiliated Hospital of Soochow University and aims to evaluate the efficacy and safety of Decitabine combined with the HAAG regimen in newly diagnosed AML patients under 60 years of age. The trial is currently recruiting participants and is expected to complete by May 2022. The market for AML treatments is competitive, with several existing therapies, including standard induction regimens like the IA regimen (Idarubicin plus Cytarabine). If successful, this trial could position Decitabine in a favorable light, potentially offering a novel treatment option that may improve overall response rates and survival outcomes, thus enhancing market share in the AML therapeutic landscape. Diligence should focus on the trial's ability to meet primary and secondary endpoints, as well as the safety profile compared to existing therapies.

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

This clinical trial, sponsored by St. Jude Children's Research Hospital, focuses on a novel approach to hematopoietic cell transplantation (HCT) for high-risk hematologic malignancies in pediatric and young adult patients. The use of TCRαβ-depleted progenitor cells combined with additional memory T-cell donor lymphocyte infusion (DLI) and the incorporation of blinatumomab presents a differentiated therapeutic strategy that may enhance engraftment and reduce the incidence of graft-versus-host disease (GVHD). The target patient population is significant, given the high unmet need in pediatric oncology, particularly for those lacking suitable HLA-matched donors. The potential for improved outcomes could position this therapy favorably against existing HCT protocols and CAR-T therapies, which are currently gaining traction in the market. The trial's results could influence future treatment guidelines and establish a competitive edge in the pediatric oncology space.

An Open-Label Phase II Study of Relatlimab (BMS-986016) With Nivolumab (BMS-936558) in Combination With 5-Azacytidine for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older Acute Myeloid Leukemia Patients

The ongoing Phase II clinical trial investigates the combination of relatlimab (Anti-LAG3), nivolumab (Anti-PD1), and 5-azacytidine in patients with refractory/relapsed Acute Myeloid Leukemia (AML) and newly diagnosed older AML patients. Given the high unmet medical need in AML, particularly among older patients who are often unfit for intensive therapies, successful outcomes could position this combination therapy as a novel treatment option in a competitive landscape dominated by traditional chemotherapeutics and emerging immunotherapies. The trial's focus on safety and tolerability, alongside efficacy measures like objective response rate (ORR), will be critical for future regulatory submissions and market access strategies. The study is being conducted by Ludwig-Maximilians University of Munich, which may enhance credibility and attract potential partnerships or investments.

Phase II Study of the Combination of 5-azacytidine With Valproic Acid and All-trans Retinoic Acid in Patients With High Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia

The combination therapy of 5-azacytidine, Valproic Acid, and All-trans Retinoic Acid targets high-risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML), a significant market with unmet needs. The successful demonstration of safety and efficacy could position this combination as a competitive treatment option in a market dominated by existing therapies such as hypomethylating agents and chemotherapy. Given the increasing focus on combination therapies in oncology, this trial's outcomes could attract interest from pharmaceutical companies looking to enhance their portfolios in hematologic malignancies. The collaboration with Celgene Corporation indicates potential commercial interest and support for further development.

Matched by conditions: Acute Myelogenous Leukemia

ABBA CORD: Double Umbilical Cord Blood Transplants With Abatacept for Graft Versus Host Disease Prophylaxis

The ABBA CORD trial, sponsored by Dr. Leland Metheny at the Case Comprehensive Cancer Center, aims to evaluate the efficacy of abatacept in reducing acute graft versus host disease (aGVHD) in patients undergoing double umbilical cord blood transplants (dCBT). Given the high incidence of aGVHD in this patient population, successful outcomes could position abatacept as a critical adjunct therapy, enhancing the standard of care which currently includes tacrolimus and mycophenolate mofetil (MMF). The trial's focus on a diverse patient demographic, particularly those with limited donor options, aligns with ongoing efforts to improve transplant outcomes in underrepresented populations. The potential market for aGVHD prophylaxis is significant, with increasing numbers of cord blood transplants being performed. Competitive analysis indicates that while anti-thymocyte globulin has been previously utilized, its decline in favorability opens a niche for abatacept if proven effective. Diligence should focus on the trial's recruitment progress and regulatory pathways for abatacept as a transplant adjunct.

An Open-Label Phase Ib/II Study of Avelumab in Combination With 5-Azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia

The combination of avelumab, a PD-L1 inhibitor, with azacitidine, an established treatment for acute myeloid leukemia (AML), targets a niche market of refractory/relapsed AML patients. The trial's termination due to a PDOL request indicates potential regulatory or strategic challenges. However, the data generated may provide insights into the immunological mechanisms of AML treatment, which could be leveraged for future product development or partnerships. The competitive landscape includes other PD-1/PD-L1 inhibitors and novel therapies for AML, necessitating a thorough diligence process to assess market positioning and potential collaborations.

Matched by conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for Patients With FLT3-ITD Positive Acute Myeloid Leukemia

The study investigates the efficacy of sorafenib maintenance therapy in patients with FLT3-ITD positive acute myeloid leukemia (AML) following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Given the prevalence of FLT3-ITD mutations in AML and the associated poor prognosis, successful outcomes from this study could enhance the therapeutic positioning of sorafenib in the AML treatment landscape. The results may influence treatment guidelines and could lead to increased market share for sorafenib, particularly in the context of maintenance therapies. Additionally, the collaboration with multiple prestigious hospitals enhances credibility and may facilitate broader acceptance and adoption of findings within clinical practice. The competitive landscape includes other FLT3 inhibitors, and the study's findings could provide a comparative advantage for sorafenib if superior outcomes are demonstrated.

Matched by conditions: Acute Myeloid Leukemia

A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

This Phase II study, sponsored by Washington University School of Medicine, aims to improve leukemia-free survival rates in patients with refractory acute myeloid leukemia (AML) through the use of cytokine-induced memory-like NK cell adoptive therapy following haploidentical donor hematopoietic cell transplantation. The target market includes high-risk AML patients, a segment with significant unmet medical needs. If successful, this therapy could position itself favorably against existing treatments, particularly in a landscape where novel immunotherapies are gaining traction. The collaboration with entities such as the NIH and ImmunityBio, Inc. suggests a strong backing that may enhance credibility and facilitate future commercialization efforts. Diligence should focus on competitive landscape analysis, particularly regarding other NK cell therapies and their clinical outcomes.

Matched by conditions: Acute Myeloid Leukemia

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

This clinical trial, sponsored by M.D. Anderson Cancer Center, aims to evaluate the efficacy of venetoclax in combination with a fractionated busulfan regimen for patients with high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The market for AML and MDS therapies is significant, with increasing demand for innovative treatments that improve patient outcomes. If successful, this trial could position venetoclax as a key component in the treatment of high-risk AML and MDS, potentially enhancing its market share against existing therapies. The trial's design includes both Phase II and Phase III components, indicating a robust approach to validating efficacy and safety, which may attract interest from investors and pharmaceutical partners. The competitive landscape includes other therapies targeting similar patient populations, necessitating a strong differentiation strategy based on clinical outcomes.

Matched by conditions: Acute Myeloid Leukemia

Prospective, Multicenter, Single-Arm Clinical Study of Mitoxantrone Liposome Combined With Azacitidine and Venetoclax in the Treatment of Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma

The clinical trial, sponsored by Ruijin Hospital, aims to evaluate the efficacy and safety of a novel liposomal formulation of Mitoxantrone combined with Azacitidine and Venetoclax in treating secondary AML, AML with extramedullary involvement, and myeloid sarcoma. The targeted patient population is significant, as these conditions often have limited treatment options and poor prognoses. The trial is currently recruiting participants, with an estimated enrollment of 48 patients. If successful, this therapy could capture a niche market within the oncology sector, particularly in regions with high unmet medical needs. The competitive landscape includes existing therapies for AML, but the unique formulation may offer advantages in terms of reduced cardiotoxicity and improved patient outcomes. Diligence should focus on the regulatory pathway, potential market access challenges, and the competitive positioning against established AML treatments.

A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60 Years of Age and Older With Previously Untreated AML

Seagen Inc. is investigating lintuzumab (SGN-33) in combination with low dose cytarabine for the treatment of acute myeloid leukemia (AML) in older patients who have declined intensive chemotherapy. The study targets a significant patient population, particularly those over 60 years of age, who are often underrepresented in clinical trials. If successful, this combination therapy could provide a new treatment option in a market characterized by limited therapies for elderly AML patients. The competitive landscape includes other therapies targeting AML, but lintuzumab's mechanism of action as a monoclonal antibody targeting CD33 may offer a differentiated approach. Diligence should focus on the safety profile, overall survival data, and potential regulatory pathways given the unmet need in this demographic.

Matched by conditions: Acute Myeloid Leukemia

A Phase 1 Trial of 8-Chloro-Adenosine in Combination With Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia

The ongoing Phase 1 trial of 8-Chloro-Adenosine in combination with Venetoclax targets relapsed/refractory acute myeloid leukemia (AML), a significant unmet medical need in oncology. The combination therapy aims to enhance anti-leukemia activity while establishing safety and tolerability. Given the competitive landscape, with several BCL-2 inhibitors already in the market, successful outcomes could position this combination as a novel treatment option, potentially leading to market differentiation. The collaboration with the National Cancer Institute (NCI) may enhance credibility and facilitate regulatory pathways. Investors should monitor enrollment rates and preliminary efficacy data closely, as these will influence future funding and partnership opportunities.

Matched by conditions: Acute Myeloid Leukemia

Bisantrene for Relapsed /Refractory Acute Myelogenous Leukemia (AML)

Bisantrene is being investigated for its efficacy in treating relapsed/refractory Acute Myelogenous Leukemia (AML), a condition with significant unmet medical need. The trial, sponsored by Sheba Medical Center, enrolled 10 patients and aims to demonstrate improved overall and leukemia-free survival rates. Given the limited treatment options for this patient population, successful outcomes could position Bisantrene as a viable therapeutic alternative, potentially capturing market share from existing therapies. The collaboration with Racura Oncology Ltd may enhance commercialization efforts, while the completion of the trial suggests readiness for further development or partnership opportunities. Stakeholders should monitor competitive responses from established AML therapies and emerging candidates in the pipeline.

Matched by conditions: Acute Myelogenous Leukemia

An Open Label, Multi-Center Study to Determine the Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia With Neutropenia

APX001 is being evaluated for its safety and pharmacokinetics in patients with Acute Myeloid Leukemia (AML) undergoing chemotherapy, a population at high risk for fungal infections due to neutropenia. The study's completion indicates that Basilea Pharmaceutica is advancing its clinical development strategy in the oncology space, particularly in addressing opportunistic infections in cancer patients. The market for antifungal therapies is competitive, with established players and emerging therapies. Successful outcomes could position APX001 favorably against existing antifungal agents, particularly in the context of oncology, where the need for effective prophylaxis is critical. Diligence should focus on the drug's efficacy, safety profile, and potential market entry barriers.

Matched by conditions: Acute Myeloid Leukemia

A Phase 1/2 Dose Evaluation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

CRISPR Therapeutics is advancing CTX131, an allogeneic CAR T cell therapy targeting CD70, into a Phase 1/2 clinical trial for adult patients with relapsed/refractory hematologic malignancies. The market for CAR T therapies is expanding, particularly in hematologic cancers, with increasing demand for innovative treatments due to the limitations of existing therapies. CTX131's unique mechanism of action may provide a competitive edge in a crowded field, especially against therapies targeting CD19 and other antigens. The successful completion of this trial could position CRISPR Therapeutics favorably for regulatory approval and market entry, enhancing its portfolio in the CAR T space and potentially leading to lucrative partnerships or acquisitions.

Matched by conditions: Acute Myeloid Leukemia

A Phase 2 Trial of Interferon-γ (IFN-γ) in Combination With Donor Leukocyte Infusion (DLI) to Treat Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) After Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)

This Phase 2 trial, led by Dr. Sawa Ito at the University of Pittsburgh, aims to evaluate the efficacy of IFN-γ in combination with donor leukocyte infusion (DLI) for patients with relapsed acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) post-allogeneic hematopoietic stem cell transplantation (alloSCT). The study addresses a significant unmet medical need in a high-risk patient population with limited treatment options. If successful, this regimen could establish a new standard of care and open avenues for additional indications of IFN-γ in the context of alloSCT. The competitive landscape includes existing therapies for AML/MDS, but the unique mechanism of action and potential for improved patient outcomes may position this therapy favorably in the market. Diligence should focus on the trial's recruitment progress and the regulatory landscape surrounding IFN-γ.

Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration

CPX-351, developed by Jazz Pharmaceuticals, is positioned to potentially offer a more effective and tolerable treatment option for adult patients with first relapse AML compared to standard intensive salvage therapies. Given the high unmet need in this patient population, successful outcomes could lead to significant market capture in the oncology sector, particularly in the AML treatment landscape. Competitive analysis indicates that while there are existing therapies, CPX-351's unique formulation may provide a differentiated profile. Diligence should focus on post-trial commercialization strategies, pricing, and reimbursement pathways, as well as potential partnerships for distribution.

Matched by conditions: Acute Myeloid Leukemia

A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

The Phase Ib study evaluating the combination of Atezolizumab and Hu5F9-G4 in relapsed or refractory acute myeloid leukemia (AML) was terminated by Hoffmann-La Roche due to the decision to discontinue development for this indication. This outcome suggests potential challenges in the therapeutic efficacy or safety profile of the combination therapy in this patient population. The AML market remains competitive with several emerging therapies, including other immunotherapies and targeted agents. The termination of this trial may impact Roche's positioning in the AML space, necessitating a reassessment of their pipeline and strategic focus on alternative indications or combinations.

Matched by conditions: Acute Myeloid Leukemia

A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies

This Phase II trial, sponsored by the Center for International Blood and Marrow Transplant Research, explores the efficacy of HLA-mismatched unrelated donor bone marrow transplantation in patients with hematologic malignancies. The trial's completion in March 2020 positions it favorably for potential market entry, particularly in the context of increasing demand for alternative donor sources in hematopoietic cell transplantation. The competitive landscape includes established therapies for hematologic malignancies, but the unique approach of utilizing mismatched donors may provide a niche advantage. Diligence should focus on the trial's safety and efficacy data, particularly regarding GVHD incidence and overall survival rates, to assess market viability and reimbursement potential.

The Incidence of Invasive Aspergillosis in Acute Myeloid Leukemia

The study conducted by University Hospital, Brest, addresses the significant morbidity and mortality associated with invasive aspergillosis (IA) in patients with acute myeloid leukemia (AML) undergoing intensive chemotherapy. The findings could influence antifungal prophylaxis practices, particularly the use of posaconazole, which may enhance patient outcomes and reduce healthcare costs associated with IA. Given the high incidence of IA in this patient population, the market for antifungal agents, particularly those targeting IA, remains robust. The competitive landscape includes established antifungals like voriconazole and newer agents, which may pose challenges for posaconazole's market share. Diligence should focus on the efficacy data and potential shifts in treatment guidelines based on this study's outcomes.

Matched by conditions: Acute Myeloid Leukemia

Department of Hematology, The Second Affiliated Hospital of Kunming Medical University.

This clinical trial is positioned to evaluate the efficacy and safety of Venetoclax in combination with a 3-day Decitabine regimen compared to the established Venetoclax and Azacitidine regimen in elderly or unfit patients with newly diagnosed Acute Myeloid Leukemia (AML). The target population is significant, as elderly patients represent a substantial segment of the AML market, often facing limited treatment options due to comorbidities. If successful, this trial could provide a competitive edge for Venetoclax in the AML treatment landscape, potentially expanding its market share against existing therapies. The trial's outcomes may influence treatment guidelines and reimbursement policies, thus impacting commercial strategies for stakeholders involved in AML therapeutics.

Matched by conditions: Elderly AML Patients

A Phase II Study of Treosulfan/Fludarabine/Low Dose Total Body Irradiation as a Preparative Regimen for Children With AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation

This Phase II study evaluates a novel preparative regimen of treosulfan, fludarabine, and low-dose TBI for pediatric patients with AML and MDS undergoing allogeneic hematopoietic cell transplantation. The primary objective is to achieve overall survival rates comparable to conventional myeloablative regimens while minimizing toxicity. Given the high unmet need in pediatric oncology, particularly in hematological malignancies, successful outcomes could position this regimen favorably in the market, potentially leading to broader adoption in clinical practice. The collaboration with established institutions and organizations, such as the Center for International Blood and Marrow Transplant Research and National Marrow Donor Program, enhances credibility and may facilitate future partnerships or licensing opportunities. However, competitive analysis indicates that other preparative regimens are also in development, necessitating ongoing diligence to assess market positioning and differentiation.

A Phase 1 Study of ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies.

Beijing InnoCare Pharma Tech Co., Ltd. is advancing ICP-248 in combination with azacitidine for the treatment of acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). The trial is currently recruiting participants across multiple sites in the United States and China, indicating a robust geographical strategy to capture diverse patient populations. The market for AML and MDS therapies is competitive, with established players like Celgene and Novartis. Successful outcomes from this trial could position InnoCare favorably within this landscape, particularly if ICP-248 demonstrates superior safety and efficacy profiles compared to existing treatments. The estimated completion of the trial in early 2028 suggests a long-term investment horizon, with potential implications for future market entry and revenue generation.

Matched by conditions: Acute Myelogenous Leukemia

CD180 CART Cell Injection in the Treatment of Relapsed or Refractory CD180 Positive Hematologic Malignancies: a Prospective, Single-arm, Single-center Clinical Study.

The CD180 CART cell therapy is being developed by the Institute of Hematology & Blood Diseases Hospital in China, focusing on relapsed or refractory acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia/lymphoma (B-ALL/LBL). The trial's single-arm design and dose escalation strategy may provide insights into the safety and efficacy of this novel therapy. Given the high unmet need in treating relapsed/refractory hematologic malignancies, successful outcomes could position this therapy favorably in a competitive landscape dominated by existing CAR-T therapies. The market for CAR-T therapies is expanding, with significant potential for growth, particularly in the Asian markets where this trial is being conducted. Diligence should focus on the trial's recruitment progress and the regulatory landscape in China, as well as potential partnerships for commercialization.

Clinical Study on the Safety and Efficacy of QN-023a Targeting CD33 in Acute Myeloid Leukemia

QN-023a, an allogeneic CAR-NK cell therapy targeting CD33, is being developed by Zhejiang University in collaboration with Hangzhou Qihan Biotech Co., Ltd. This Phase I trial aims to address a significant unmet need in relapsed/refractory Acute Myeloid Leukemia (AML), a condition with limited treatment options and poor prognosis. The market for AML therapies is competitive, with several emerging therapies, including CAR-T and novel small molecules. Successful outcomes from this trial could position QN-023a favorably within the oncology landscape, particularly if it demonstrates a favorable safety and efficacy profile compared to existing therapies. The trial's design and the targeted patient population suggest a focused approach that may attract interest from potential partners or investors, especially given the increasing demand for innovative cancer treatments.

Matched by conditions: AML, Adult

An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients

Jazz Pharmaceuticals' CPX-351 is positioned in a competitive landscape focused on acute leukemias and MDS, which are areas of significant unmet medical need. The drug's unique liposomal formulation may provide a therapeutic advantage over traditional chemotherapy, potentially leading to improved patient outcomes. The successful completion of this Phase II trial could enhance Jazz's portfolio and market presence, especially if the results demonstrate a favorable safety and efficacy profile. Given the stringent eligibility criteria and the focus on QTc prolongation, the asset may attract interest from regulatory bodies and investors, particularly in light of the growing emphasis on cardiac safety in oncology treatments.

High-Dose Ara-C Followed by Continuous Infusion Interleukin-2 for Acute Myelogenous Leukemia in First Remission

The study conducted by Dana-Farber Cancer Institute investigates the combination of high-dose ara-C and continuous infusion IL-2 in patients with AML in first remission. Given the high unmet need in AML treatment, particularly for patients in remission, this trial could provide valuable data on the efficacy and safety of this combination therapy. The results may position Dana-Farber as a leader in innovative AML therapies, potentially attracting partnerships or investments. The competitive landscape includes established therapies such as chemotherapy and emerging immunotherapies, necessitating a thorough analysis of clinical outcomes to assess market positioning. The findings could influence future treatment guidelines and reimbursement strategies.

Matched by conditions: Acute Myelogenous Leukemia

A Phase 1 Study of MLN518 Given in Combination With Standard Induction Chemotherapy for the Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia

MLN518, developed by Millennium Pharmaceuticals, Inc., is being evaluated in a Phase 1 clinical trial for its efficacy in combination with standard induction chemotherapy in newly diagnosed AML patients. The market for AML therapies is competitive, with several approved agents and ongoing clinical trials. The successful demonstration of safety and efficacy could position MLN518 favorably in a market that is increasingly focused on combination therapies. Given the high unmet need in AML, particularly for patients with poor prognostic factors, MLN518 could capture significant market share if it demonstrates improved outcomes over existing therapies. Diligence should focus on the trial's safety profile, potential for dose adjustments based on plasma concentrations, and the overall response rates in the context of current treatment paradigms.

A Single-arm, Pilot Study of Venetoclax in Combination With 5 Days Azacitidine in Treatment-naïve Subjects With Acute Myelogenous Leukemia Who Are ≥18 Years of Age and Not Eligible for Standard Induction Therapy (VENAZA-5S PILOT TRIAL)

The VENAZA-5S pilot trial is exploring a modified treatment regimen of Venetoclax in combination with a reduced duration of Azacitidine for treatment-naïve patients with Acute Myeloid Leukemia (AML) who are ineligible for standard induction therapy. This study aims to enhance tolerability and adherence, potentially leading to improved patient outcomes and quality of life. The market for AML therapies is growing, driven by the increasing incidence of the disease and the need for effective treatments for elderly and comorbid patients. AbbVie’s involvement as a collaborator indicates strategic interest in expanding the Venetoclax portfolio, which could enhance competitive positioning against other therapies in the AML space. The results of this trial may provide critical data to support further development and commercialization strategies, particularly in Europe where the standard of care is evolving.

A Phase 2 Trial of Fractionated Gemtuzumab Ozogamicin to Eradicate Measurable Residual Disease in Acute Myeloid Leukemia Patients (GO for MRD)

The ongoing Phase 2 trial of fractionated gemtuzumab ozogamicin (GO for MRD) is sponsored by the University of Washington, in collaboration with Pfizer. This trial aims to evaluate the efficacy of gemtuzumab ozogamicin in eradicating measurable residual disease (MRD) in AML patients. The targeted therapy approach may position this asset favorably in the competitive landscape, particularly as the treatment of AML continues to evolve with a focus on precision medicine. The successful outcome of this trial could enhance the market potential for gemtuzumab ozogamicin, especially given the unmet need for effective therapies in MRD-positive AML patients. The trial is currently recruiting, with an estimated completion date in December 2026, which may allow for timely entry into the market if results are favorable.

Matched by conditions: Acute Myeloid Leukemia